Because some tumor blood vessels may be formed by a “mosaic” consisting of both bona fide ECs that are closely juxtaposed to cancer cells, VM presents a challenge for anti-angiogenic approaches (mainly because many VM-competent cancer cells do not express receptors for typical pro-angiogenic factors such as VEGF) [106]. This evidence concerns the gene VEGFA and neoplasm.